scholarly journals αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease

2015 ◽  
Vol 46 (2) ◽  
pp. 486-494 ◽  
Author(s):  
Gauri Saini ◽  
Joanne Porte ◽  
Paul H. Weinreb ◽  
Shelia M. Violette ◽  
William A. Wallace ◽  
...  
Keyword(s):  
Lung Disease ◽  
Smooth Muscle Actin ◽  
Treatment Options ◽  
Surfactant Protein ◽  
Interstitial Lung Diseases ◽  
Tissue Sections ◽  
Αvβ6 Integrin ◽  
Fibrotic Lung Disease ◽  
Relationship Of ◽  
The Relationship

Idiopathic pulmonary fibrosis (IPF) and fibrotic nonspecific interstitial pneumonitis are progressive interstitial lung diseases (ILDs) with limited treatment options and poor survival. However, the rate of disease progression is variable, implying there may be different endotypes of disease. We hypothesised that immunophenotyping biopsies from ILD patients might reveal distinct endotypes of progressive fibrotic disease, which may facilitate stratification when undertaking clinical trials of novel therapies for IPF.43 paraffin-embedded, formalin-fixed lung tissue sections were immunostained for five molecules implicated in the pathogenesis of the fibrosis: α-smooth muscle actin (αSMA), αvβ6 integrin, pro-surfactant protein C (SP-C), hepatocyte growth factor (HGF) and tenascin-C (TenC). Levels of immunostaining and numbers of fibroblastic foci were quantified using operator-dependent and -independent methods. The relationship of all these markers to overall survival was analysed.Staining revealed high levels of αSMA, αvβ6 integrin, pro-SP-C, HGF and TenC, and fibroblastic foci. Immunostaining varied across samples for all molecules but only the extent of αvβ6 integrin immunostaining was associated with increased mortality. There was no association with the other markers measured.Our data suggest high levels of αvβ6 integrin may identify a specific endotype of progressive fibrotic lung disease.

Establishing a Group Educational Session for Hyperacusis Patients

2019 ◽  
Vol 28 (2) ◽  
pp. 245-250
Author(s):  
Ann E. Perreau ◽  
Richard S. Tyler ◽  
Patricia C. Mancini ◽  
Shelley Witt ◽  
Mohamed Salah Elgandy
Keyword(s):  
Therapeutic Process ◽  
Treatment Options ◽  
Clinical Group ◽  
Education Session ◽  
Group Approach ◽  
Treatment Protocols ◽  
Educational Session ◽  
Evidence Based Treatment ◽  
Relationship Of ◽  
The Relationship

Purpose Audiologists should be treating hyperacusis patients. However, it can be difficult to know where to begin because treatment protocols and evidence-based treatment studies are lacking. A good place to start in any tinnitus and hyperacusis clinic is to incorporate a group educational session. Method Here, we outline our approach to establishing a hyperacusis group educational session that includes specific aspects of getting to know each patient to best meet their needs, understanding the problems associated with hyperacusis, explaining the auditory system and the relationship of hyperacusis to hearing loss and tinnitus, describing the influence of hyperacusis on daily life, and introducing treatment options. Subjective responses from 11 adults with hyperacusis, who participated in a recent clinical group education session, were discussed to illustrate examples from actual patients. Conclusions Due to the devastating nature of hyperacusis, patients need to be reassured that they are not alone and that they can rely on audiologists to provide support and guidance. A group approach can facilitate the therapeutic process by connecting patients with others who are also affected by hyperacusis, and by educating patients and significant others on hyperacusis and its treatment options. Supplemental Material https://doi.org/10.23641/asha.8121197

scholarly journals Study of the relationship of dyspnea with depression and functional status in patients with interstitial lung disease

2015 ◽  
Vol 64 (1) ◽  
pp. 269-275 ◽  
Author(s):  
Hoda A. Abu Youssef ◽  
Youssriah Y. Sabry ◽  
Mohamed N. Sadek ◽  
Marwa M. Shaban ◽  
Sameh I. Hafez
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Functional Status ◽  
Relationship Of ◽  
The Relationship

Is Chronic Lung Disease in Low Birth Weight Infants Preventable? A Survey of Eight Centers

PEDIATRICS ◽  
1987 ◽  
Vol 79 (1) ◽  
pp. 26-30 ◽  
Author(s):  
Mary Ellen Avery ◽  
William H. Tooley ◽  
Jacob B. Keller ◽  
Suzanne S. Hurd ◽  
M. Heather Bryan ◽  
...  
Keyword(s):  
Birth Weight ◽  
Low Birth Weight ◽  
Lung Disease ◽  
San Francisco ◽  
Chronic Lung Disease ◽  
Multivariate Logistic Regression Analysis ◽  
Low Birth Weight Infants ◽  
Relationship Of ◽  
The Relationship ◽  
Prematurely Born Infants

Chronic lung disease in prematurely born infants, defined as the need for increased inspired oxygen at 28 days of age, was thought to be more common in some institutions than in others. To test this hypothesis, we surveyed the experience in the intensive care nurseries at Columbia and Vanderbilt Universities, the Universities of Texas at Dallas, Washington at Seattle, and California at San Francisco, the Brigham and Women's Hospital in Boston, Texas Children's Hospital in Houston, and Mt Sinai Hospital in Toronto. The survey included 1,625 infants with birth weights of 700 to 1,500 g. We confirmed the relationship of risk to low birth weight, white race, and male sex. Significant differences in the incidence of chronic lung disease were found between institutions even when birth weight, race, and sex were taken into consideration through a multivariate logistic regression analysis. Columbia had one of the best outcomes for low birth weight infants and the lowest incidence of chronic lung disease.

Immunomodulation in Autoimmune Interstitial Lung Disease

Respiration ◽  
2020 ◽  
Vol 99 (10) ◽  
pp. 819-829
Author(s):  
Benjamin Seeliger ◽  
Antje Prasse
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Systemic Disease ◽  
Treatment Options ◽  
Interstitial Lung Diseases ◽  
Treatment Modalities ◽  
Established Disease ◽  
Synthetic Dmards ◽  
New Treatment ◽  
Underlying Diseases

Interstitial lung diseases (ILDs) associated with autoimmune or systemic disease are increasingly recognized and our pathophysiological understanding rapidly expanding. Treatment modalities, however, are still mainly driven by established disease-modifying antirheumatic drugs (DMARDs) where, despite decades of experience of their use in the underlying diseases such as rheumatoid arthritis, mostly ret­rospective data exist informing their effect on the course of interstitial lung disease (ILD). In recent years, randomized trials investigating the effects of biological DMARDs (bDMARDs) have been completed or are currently running, generating new treatment options for often relentlessly progressive diseases. Herein, we summarize the evidence and current use of both synthetic DMARDs and bDMARDs in the context of ILDs associated with autoimmune/systemic disease.

The Relationship of the 6-Min Walk Test to Maximal Oxygen Consumption in Transplant Candidates With End-Stage Lung Disease

CHEST Journal ◽  
1995 ◽  
Vol 108 (2) ◽  
pp. 452-459 ◽  
Author(s):  
Lawrence Cahalin ◽  
Paul Pappagianopoulos ◽  
Stella Prevost ◽  
John Wain ◽  
Leo Ginns
Keyword(s):  
Oxygen Consumption ◽  
Lung Disease ◽  
Maximal Oxygen Consumption ◽  
Walk Test ◽  
Transplant Candidates ◽  
End Stage ◽  
Relationship Of ◽  
The Relationship

scholarly journals The relationship of SSRI and SNRI usage with interstitial lung disease and bronchiectasis in an elderly population: a case–control study

2017 ◽  
Vol Volume 12 ◽  
pp. 1977-1984 ◽  
Author(s):  
Ted Rosenberg ◽  
Rory Lattimer ◽  
Patrick Montgomery ◽  
Christian Wiens ◽  
Liran Levy
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Elderly Population ◽  
Relationship Of ◽  
The Relationship ◽  
Control Study

scholarly journals LACTOFERRIN, FLUORESCENT TECHNOLOGIES AND THEIR ROLE IN THE DIAGNOSIS AND TREATMENT OF INFLAMMATORY DISEASES OF THE FEMALE SEXUAL SPHERE

2018 ◽  
Vol 5 (2) ◽  
pp. 101-105
Author(s):  
V. M Zuev ◽  
D. G Gulenkova ◽  
I. L Goldman ◽  
E. R Sadchikova ◽  
M. T Aleksandrov
Keyword(s):  
Inflammatory Diseases ◽  
Scientific Evidence ◽  
Treatment Options ◽  
Rapid Assessment ◽  
Intrauterine Infection ◽  
Infectious Complications ◽  
Vaginal Infections ◽  
Vaginal Microflora ◽  
Relationship Of ◽  
The Relationship

The article reflects a modern view on the introduction of fluorescent methods of diagnostics and treatment of vaginal infections using lactoferrin in clinical microbiology, which made it possible to expand microecological studies. The suppression of the normal vaginal microflora was shown to promote a diverse pathology of both inflammatory and non-inflammatory genesis. Bacterial and fungal vaginosis were proved to be the most important risk factors for the development of infectious complications in the gynecological practice. There are given substantiated scientific evidence, indicating a large number of recurrences of bacterial and candidal vaginitis, despite the numerous studies and various treatment options. The relationship of bacterial vaginitis with infertility, the threat of miscarriage, premature birth, intrauterine infection of the fetus, etc. was established. Based on this, the search for alternative combined methods is relevant. The aim of the study was to increase the effectiveness of the treatment of recurrent candid vulvovaginitis and bacterial vaginosis by using lactoferrin. In the study, there were used fluorescent methods of the diagnosis, which made it possible to verify the diagnosis in the rapid assessment mode, as well as monitor treatment and improve its effectiveness.

Sign in / Sign up

Export Citation Format

Share Document